0001179110-21-008010.txt : 20210809
0001179110-21-008010.hdr.sgml : 20210809
20210809072116
ACCESSION NUMBER: 0001179110-21-008010
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210805
FILED AS OF DATE: 20210809
DATE AS OF CHANGE: 20210809
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Marucci Anthony S
CENTRAL INDEX KEY: 0001429933
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-15006
FILM NUMBER: 211154622
MAIL ADDRESS:
STREET 1: 66 COLD HILL DRIVE
CITY: MENDAHM
STATE: NJ
ZIP: 07945
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celldex Therapeutics, Inc.
CENTRAL INDEX KEY: 0000744218
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 133191702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
BUSINESS PHONE: 908-200-7500
MAIL ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
FORMER COMPANY:
FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19980828
FORMER COMPANY:
FORMER CONFORMED NAME: T CELL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
edgar.xml
FORM 4 -
X0306
4
2021-08-05
0
0000744218
Celldex Therapeutics, Inc.
CLDX
0001429933
Marucci Anthony S
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD
HAMPTON
NJ
08827
1
1
0
0
President & CEO
Common Stock
2021-08-05
4
M
0
3537
42.00
A
27231
D
Incentive Stock Option
42.00
2021-08-05
4
M
0
3537
0.00
D
2021-08-05
Common Stock
3537
0
D
Includes 4,256 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Option Plan. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
This option was previously reported as covering 180,400 shares at an exercise price of $2.80 per share, but has been adjusted to reflect the Reverse Stock Split. The remaining 8,488 shares of common stock underlying the option expired on August 5, 2021.
As of August 5, 2015, the option is fully vested.
/s/ Samuel B. Martin, attorney in fact for Anthony S. Marucci
2021-08-09